Last updated on March 2018

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)


Brief description of study

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM).

The drugs involved in this study are :

  • Abemaciclib
  • Temozolomide (temodar)
  • Neratinib
  • CC115

Detailed Study Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the study drug works in treating a specific disease. "Investigational" means that the drug is being studied.

In this research study, the investigators are looking to compare the effects, good and bad, of the standard of care with the three investigational agent sub-studies Abemaciclib, Neratinib, CC115 to help people with Glioblastoma including the specific molecular changes in the genes and proteins.

The FDA has approved Temozolomide (temodar) as a treatment for this disease, however the FDA has not approved Abemaciclib, CC115, Neratinib for any diseases.

Clinical Study Identifier: NCT02977780

Find a site near you

Start Over

University of Virginia Health System

Charlottesville, VA United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.